title: Induction of effective antitumor immune responses in a mouse bladder tumor model by using DNA of an alpha antigen from mycobacteria.
abstract: One of the main objectives of cancer immunotherapy is the activation and increase in number of antitumor effector cells. Recently, genetically modified tumor cell vaccines have been proposed for elicitation of antitumor effector cells. Native alpha antigen (alpha Ag) (also known as MPT59 and antigen 85B) of mycobacteria, which cross-reacts among mycobacteria species, may play an important biological role in host-pathogen interaction because it elicits various helper T-cell type 1 immune responses. To assess the induction of antitumor immune responses by alpha Ag, mouse tumor cell lines transfected with cDNA of alpha Ag from Mycobacterium kansasii were established, and the possibility of producing a tumor cell vaccine for induction of antitumor effects was explored. Transfection of tumor cell lines with an alpha Ag gene lead to primary tumor rejection and the establishment of protective immunity to nontransfected original tumor cell lines in Mycobacterium bovis bacillus Calmette-Gurin (BCG)-primed and unprimed mice. Mice immunized with tumor cell lines transfected with the alpha Ag gene showed delayed-type hypersensitivity responses in vivo and proliferative responses together with induction of interferon-gamma of spleen cells against nontransfected wild-type tumor cell lines in in vitro experiments. Moreover, immunization of mice with alpha Ag-expressing tumor cells elicited tumor-specific and cytotoxic T lymphocyte (CTL) epitope peptide-specific CD8+ CTLs. The results of this study provided evidence of the potential usefulness of alpha Ag in tumor cell vaccines.
authors.affiliation: Department of Bioregulation, Mie University School of Medicine, Mie 514-8507, Japan.
authors.forename: I
authors.initials: I
authors.lastname: Kuromatsu
authors.forename: K
authors.initials: K
authors.lastname: Matsuo
authors.forename: S
authors.initials: S
authors.lastname: Takamura
authors.forename: G
authors.initials: G
authors.lastname: Kim
authors.forename: Y
authors.initials: Y
authors.lastname: Takebe
authors.forename: J
authors.initials: J
authors.lastname: Kawamura
authors.forename: Y
authors.initials: Y
authors.lastname: Yasutomi
mesh_terms: D000818:Animals; D000942:Antigens, Bacterial / Q000235:genetics*; D019496:Cancer Vaccines; D004247:DNA / Q000235:genetics*; D015316:Genetic Therapy / Q000379:methods*; D007371:Interferon-gamma / Q000096:biosynthesis; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D009163:Mycobacterium bovis / Q000276:immunology / Q000378:metabolism; D010452:Peptide Biosynthesis; D013154:Spleen / Q000166:cytology; D013602:T-Lymphocytes, Cytotoxic / Q000378:metabolism; D013997:Time Factors; D014162:Transfection; D014407:Tumor Cells, Cultured; D001749:Urinary Bladder Neoplasms / Q000276:immunology* / Q000628:therapy*
chemical_list: D000942:Antigens, Bacterial; D019496:Cancer Vaccines; C052242:alpha antigens, Mycobacterium; D007371:Interferon-gamma; D004247:DNA